Other Publications Referenced in Amarin’s Investor Communications ≪ Back to Publications To search publications using the available search words, please click here: New insights into icosapent ethyl for patients with residual cardiovascular risk. Radenkovic D, Olshansky B, Bhatt D. New insights into icosapent ethyl for patients with residual cardiovascular risk. EMJ Cardiol. 2020;8:34-40. https://www.emjreviews.com/cardiology/symposium/new-insights-into-icosapent-ethyl-for-patients-with-residual-cardiovascular-risk/ cardiovascular risk icosapent ethyl IPE REDUCE-IT trial triglycerides Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Olshansky B, Chung MK, Budoff MJ, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J. 2020;22(Supplement J):J34-J48. https://doi.org/10.1093/eurheartj/suaa117 hsCRP IPE LDL-C mineral oil placebo REDUCE-IT trial safety statin triglycerides
New insights into icosapent ethyl for patients with residual cardiovascular risk. Radenkovic D, Olshansky B, Bhatt D. New insights into icosapent ethyl for patients with residual cardiovascular risk. EMJ Cardiol. 2020;8:34-40. https://www.emjreviews.com/cardiology/symposium/new-insights-into-icosapent-ethyl-for-patients-with-residual-cardiovascular-risk/ cardiovascular risk icosapent ethyl IPE REDUCE-IT trial triglycerides
Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Olshansky B, Chung MK, Budoff MJ, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J. 2020;22(Supplement J):J34-J48. https://doi.org/10.1093/eurheartj/suaa117 hsCRP IPE LDL-C mineral oil placebo REDUCE-IT trial safety statin triglycerides